Royalty and Commercial Payment Purchase Agreements - Viracta (Details) $ in Thousands |
12 Months Ended | |||
|---|---|---|---|---|
|
Mar. 22, 2021
USD ($)
item
|
Dec. 31, 2021
USD ($)
|
Dec. 31, 2020
USD ($)
|
Dec. 31, 2019
USD ($)
|
|
| Agreements | ||||
| Payments related to purchase of royalty rights and other commercial payment rights | $ 26,500 | $ 1,200 | ||
| Long-term royalty and commercial payment receivables | 69,075 | 34,575 | $ 34,375 | |
| Impairment of long-term royalty receivable | 0 | $ 0 | ||
| Viracta | Royalty Purchase Agreement | ||||
| Agreements | ||||
| Number of drug candidates | item | 2 | |||
| Payments related to purchase of royalty rights and other commercial payment rights | $ 13,500 | |||
| Maximum amount of potential milestones and other payments receivable | 54,000 | |||
| Amount of maximum consideration retained | 20,000 | |||
| Maximum amount of potential regulatory and commercial milestones receivable | 57,000 | |||
| Long-term royalty and commercial payment receivables | $ 13,500 | |||
| Impairment of long-term royalty receivable | $ 0 | |||
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Number of drug candidates under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Definition The aggregate amount of write-downs for impairments recognized during the period for long term royalty receivable assets. No definition available.
|
| X | ||||||||||
- Definition Long-term royalty and commercial rights receivables, non current. No definition available.
|
| X | ||||||||||
- Definition Amount of maximum consideration retained by Company excluded from maximum potential milestones under terms of agreement. No definition available.
|
| X | ||||||||||
- Definition Maximum amount of potential milestones and other payments receivable, excluding consideration retained by company under the terms of the agreement. Excludes regulatory and commercial milestones. No definition available.
|
| X | ||||||||||
- Definition Payments related to purchase of royalty rights and other commercial payment rights. No definition available.
|
| X | ||||||||||
- Definition Maximum amount of potential regulatory and commercial milestones receivable under the terms of the agreement. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|